SK plasma to supply $30 million worth of blood products to Singapore for 6 years
https://www.koreabiomed.com/news/articleView.html?idxno=21445SK plasma said it has received approval from the Singaporean Health Sciences Authority (HSA) for its blood products -- albumin and immunoglobulin -- and began full-scale production in June.
Under the accord, Singapore's health authorities will supply plasma from their own blood sources to SK plasma, which will use the plasma as raw material to produce finished blood products such as albumin at its Andong plant and send them back to Singapore.
SK plasma plans to process and export approximately 20,000 liters of blood products annually to Singapore.
SK plasma stressed that the contract manufacturing deal for its blood products in Singapore is an achievement that shows the company's superior technology in a global market that multinational pharmaceutical companies have monopolized.
"This is the first exclusive blood product processing export to an EU GMP level country, and it is a case of recognition of SK plasma's technology," SK plasma CEO Kim Seung-ju said. "Based on this achievement, we will continue to expand our global business."
Blood products are medicinal substances derived from blood. They are produced by fractionating and purifying the components of blood, such as albumin and immunoglobulin. These products play a critical role in the treatment of various conditions, including excessive blood loss-induced shock, congenital immunodeficiency diseases, and hemophilia.
In addition, blood products such as albumin and immunoglobulin are widely needed in national disaster situations and are designated and managed as national essential drugs.
